Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

AIDS Healthcare Foundation Asks FDA to Withdraw Approval of GSK's Antiretroviral Drug Trizivir

August 20, 2003

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

AIDS Healthcare Foundation, the largest nongovernmental provider of health care services for people with HIV/AIDS in the United States, yesterday sent a letter to the FDA asking that it withdraw approval of GlaxoSmithKline's antiretroviral drug Trizivir after an NIH study indicated that the drug was less effective than other antiretrovirals, Reuters reports. Trizivir combines three antiretroviral drugs -- zidovudine, lamivudine, and abacavir -- into one pill taken twice daily in order to simplify treatment regimens (Reuters, 8/19). According to interim data released in March from the NIH study, Trizivir is inferior to similar drug regimens that contain Bristol Myers-Squibb's Sustiva in treating HIV-positive patients who have never taken antiretroviral drugs. Based on the data from the double-blind, placebo-matched clinical trial, researchers stopped one arm of the study because patients taking Trizivir experienced virologic failure -- defined as having a viral load level above 200 copies/ml at least four months after beginning the treatment -- sooner and more often than patients in the other two arms of the study. The other two treatment regimens being evaluated include a combination of lamivudine and zidovudine -- Glaxo's Combivir -- plus Sustiva, or a combination of Trizivir and Sustiva (Kaiser Daily HIV/AIDS Report, 3/13). AHF said that based on the NIH findings, it is "apparent that Trizivir may be effective only if it is taken with other HIV/AIDS drugs." AHF added that keeping Trizivir on the market could be dangerous because not all doctors with HIV-positive patients are aware of the study findings and could continue to prescribe the drug alone. GSK spokesperson Nancy Pekarek said that AHF was "acting irresponsibly," adding that the NIH study should be considered "in the context of the total available data, which proves the effectiveness of Trizivir." In addition, Pekarek said that an HHS expert panel in July issued guidelines recommending the drug as a first-choice HIV treatment option. An FDA spokesperson said that the agency plans to review AHF's request (Reuters, 8/19).

Back to other news for August 20, 2003


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2003 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More Research on Trizivir (AZT/3TC/Abacavir)

Tools
 

Advertisement